Publications by authors named "Mark Thalgott"

Claim this Profile
O
Outpatient vs. Inpatient Ureterorenoscopy - A Retrospective Dual-Center Analysis.
Maximilian Reinhard Müller, Marco Julius Schnabel, Immanuel Augustin Oppolzer, Christopher Goßler, Maximilian Burger, Mark Thalgott

Urol Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy.
Lukas Lunger, Margitta Retz, Miriam Bandur, Marc Souchay, Elisabeth Vitzthum, Mark Thalgott

Prostate Cancer Prostatic Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Stop-Shop Whole-Body Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer.
Mark Thalgott, Charlotte Düwel, Isabel Rauscher, Matthias M Heck, Bernhard Haller

J Nucl Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.
Matthias M Heck, Margitta Retz, Miriam Bandur, Marc Souchay, Elisabeth Vitzthum, Mark Thalgott

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.
Mark Thalgott, Martina Kron, Johannes M Brath, Donna P Ankerst, Ian M Thompson

World J Urol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, Roman Nawroth, Robert Tauber, Mark Thalgott

Eur Urol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Matthias M Heck, Markus A Thaler, Sebastian C Schmid, Anna-Katharina Seitz, Robert Tauber, Mark Thalgott

BJU Int· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy.
Thomas Horn, Tina Zahel, Nathanja Adt, Sebastian C Schmid, Matthias M Heck, Mark K Thalgott

Urol Int· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of [C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.
Sarah M Schwarzenböck, Matthias Eiber, Günther Kundt, Margitta Retz, Monique Sakretz, Mark Thalgott

Eur J Nucl Med Mol Imaging· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.
Thomas Mücke, Herbert Deppe, Jana Hein, Klaus-Dietrich Wolff, David A Mitchell, Mark Thalgott

J Craniomaxillofac Surg· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Matthias M Heck, Mark Thalgott, Sebastian C Schmid, William K Oh, Yixuan Gong

Prostate· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy.
Sarah M Schwarzenböck, Anna Knieling, Michael Souvatzoglou, Jens Kurth, Katja Steiger, Mark Thalgott

Oncotarget· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
Günter Niegisch, Margitta Retz, Mark Thalgott, Stefan Balabanov, Friedemann Honecker

Oncology· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1.
Anuja Sathe, Nicole Koshy, Sebastian C Schmid, Mark Thalgott, Sarah M Schwarzenböck

J Urol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome.
Georgios Hatzichristodoulou, Stefan Wagenpfeil, Gregor Weirich, Michael Autenrieth, Tobias Maurer, Mark Thalgott

World J Urol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
Mark Thalgott, Brigitte Rack, Thomas Horn, Matthias M Heck, Matthias Eiber

Anticancer Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.
Tobias Maurer, Gregor Weirich, Margret Schottelius, Martina Weineisen, Benjamin Frisch, Mark Thalgott

Eur Urol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Mark Thalgott, Brigitte Rack, Matthias Eiber, Michael Souvatzoglou, Matthias M Heck

BMC Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Matthias M Heck, Margitta Retz, Miriam Bandur, Marc Souchay, Elisabeth Vitzthum, Mark Thalgott

Eur Urol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.
Matthias M Heck, Michael Souvatzoglou, Margitta Retz, Roman Nawroth, Hubert Kübler, Mark Thalgott

Eur J Nucl Med Mol Imaging· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Mark Thalgott, Thomas Horn, Matthias M Heck, Tobias Maurer, Matthias Eiber

J Hematol Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of circulating tumor cells in different stages of prostate cancer.
Mark Thalgott, Brigitte Rack, Tobias Maurer, Michael Souvatzoglou, Matthias Eiber

J Cancer Res Clin Oncol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inguinal lymph node dissection: epidermal vacuum therapy for prevention of wound complications.
Robert Tauber, Sebastian Schmid, Thomas Horn, Mark Thalgott, Matthias Heck

J Plast Reconstr Aesthet Surg· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Matthias M Heck, Mark Thalgott, Margitta Retz, Petra Wolf, Tobias Maurer

BJU Int· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus.
Thomas Horn, Mark K Thalgott, Tobias Maurer, Katharina Hauner, Stephan Schulz

Anticancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis